Key Developments

In October 2023, a study compared SPRAVATO nasal spray, of Janssen Pharmaceuticals, Inc, a pharmaceutical company with quetiapine XR in treating treatment resistant depression (TRD). SPRAVATO showed better remission rates after eight weeks and longer-term relapse-free periods. Adverse events were consistent with known safety profiles. The study's limitations include its open-label design and differences in treatment compliance and administration routes. However, it provides valuable insights for physicians managing TRD, offering patients additional treatment options.
In August 2022, Merck Sharp & Dohme LLC, a biopharmaceutical company commenced, Phase II A Clinical Trial to assess the safety and efficacy of MK-1942 in patients with treatment resistant depression
In July 2022, Novartis Pharmaceuticals, a Switzerland-based multinational pharmaceutical corporation, announced plans to begin a Phase 2 clinical trial of MIJ821 (ketamine) for the treatment of treatment resistant depressive disorders in September 2022
In May 2022, COMPASS Pathways, a biotechnology company, presented positive results from the Phase IIb study of COMP360 psilocybin therapy for the treatment of treatment resistant depression at the American Psychiatric Association annual meeting in New Orleans
In February 2022, Denova Biopharma, a private San Diego-based biotech company, obtained the USFDA approval to initiate a Phase 2b clinical trial to investigate the efficacy and safety of DB104 (liafensine) in patients with treatment resistant mood disorders
In December 2021, Dr. Reddy, a multinational pharmaceutical company, introduced a product equivalent to Venlafaxine extended release, an antidepressant tablet, following approval from the U.S. Food and Drug Administration.